Fig. 4.
Fig. 4. Cell surface expression of CCR5 by monocytes. / Monocytes incubated with different reagents were stained with an FITC-conjugated anti-CCR5 monoclonal antibody (2D7) and analyzed for the percentage of positively stained populations by flow cytometry. (A) Cells incubated with medium and stained with FITC-conjugated mouse IgG. (B) Cells incubated with medium and stained with FITC–anti-CCR5. (C) Cells treated with MIP-1α (1 μg/mL, 15 minutes, 37°C) and stained with FITC–anti-CCR5. (D) Cells treated with fMLF (10−6mol/L, 60 minutes, 37°C), then stained with FITC–anti-CCR5. (E) Cells pretreated with staurosporine (Stauro; 1.4 ng/mL, 30 minutes, 37°C) followed by fMLF (10−6 mol/L, 60 minutes, 37°C) and then stained with FITC–anti-CCR5.

Cell surface expression of CCR5 by monocytes.

Monocytes incubated with different reagents were stained with an FITC-conjugated anti-CCR5 monoclonal antibody (2D7) and analyzed for the percentage of positively stained populations by flow cytometry. (A) Cells incubated with medium and stained with FITC-conjugated mouse IgG. (B) Cells incubated with medium and stained with FITC–anti-CCR5. (C) Cells treated with MIP-1α (1 μg/mL, 15 minutes, 37°C) and stained with FITC–anti-CCR5. (D) Cells treated with fMLF (10−6mol/L, 60 minutes, 37°C), then stained with FITC–anti-CCR5. (E) Cells pretreated with staurosporine (Stauro; 1.4 ng/mL, 30 minutes, 37°C) followed by fMLF (10−6 mol/L, 60 minutes, 37°C) and then stained with FITC–anti-CCR5.

Close Modal

or Create an Account

Close Modal
Close Modal